Correlation Engine 2.0
Clear Search sequence regions

  • cancer (8)
  • humans (1)
  • ligand (1)
  • measures (1)
  • patient (7)
  • prostate (6)
  • Sizes of these terms reflect their relevance to your search.

    The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings. © 2023 by the Society of Nuclear Medicine and Molecular Imaging.


    Lisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R Armstrong, Khaled Komrokji, Laura B Oswald, Heather S L Jim, Ghassan El-Haddad, Wolfgang P Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S Hofman, Adam P Dicker, Jeremie Calais, Scott T Tagawa, Brian D Gonzalez. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Jun;64(6):869-872

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36635088

    View Full Text